刘竺云,刘媛,杨珊珊,沙赟颖,周国春.化学通报,2024,87(1):86-91. |
抗癌药替沃扎尼的合成研究进展 |
ProgressintheSynthesisoftheAnticancerDrugTevozanib |
投稿时间:2023-06-12 修订日期:2023-07-30 |
DOI: |
中文关键词: 替沃扎尼 酪氨酸激酶抑制剂 肾细胞癌 |
英文关键词:Tivozanib,Tyrosine kinase inhibitors,Renal cell carcinoma |
基金项目:江苏省第六期“333高层次人才培养工程”第三层次人才项目、2023年江苏省高等学校基础科学(自然科学)研究项目(23KJD350004)、2021年泰州市科技支撑计划(社会发展)项目(SSF20210034)和2022年泰州职业技术学院院级重点科研项目(TZYKYZD-22-2)资助 |
|
摘要点击次数: 1368 |
全文下载次数: 232 |
中文摘要: |
肾细胞癌(亦称肾癌)是最常见的侵袭性恶性肿瘤之一,而对于晚期肾癌,药物治疗尤为关键。小分子靶向新药替沃扎尼是一种口服、强效、高选择性和安全性的VEGFR酪氨酸激酶受体抑制剂,具有明显的抗肿瘤及抗血管生成作用,市场应用前景广阔。本文总结了替沃扎尼的合成方法、晶型类别,并讨论了各合成方法的优缺点,为替沃扎尼及其中间体的合成研究和工业化生产提供帮助。 |
英文摘要: |
Renal cell carcinoma, also known as renal carcinoma, is one of the most common invasive malignant tumors, and for advanced renal cell carcinoma, drug treatment is particularly crucial. Tivozanib, a small molecule targeted new drug, is an oral, potent, highly selective, and safe VEGFR tyrosine kinase receptor inhibitor with significant anti-tumor and anti angiogenic effects, and has broad market application prospects. This article summarizes the synthesis methods and crystal types of Tivozanib, and discusses the advantages and disadvantages of each synthesis method, providing assistance for the synthesis research and industrial production of Tivozanib and its intermediates. |
查看全文 查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|